<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898322</url>
  </required_header>
  <id_info>
    <org_study_id>SY005002</org_study_id>
    <nct_id>NCT04898322</nct_id>
  </id_info>
  <brief_title>SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis</brief_title>
  <official_title>A Phase IIa Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Intravenous Injection of SY-005 in Sepsis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase IIa Randomized, Double-blind, Parallel Group, Placebo-controlled, multicenter&#xD;
      Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Intravenous&#xD;
      Injection of SY-005（recombinant human annexin A5） in Sepsis Subjects. 96 patients will be&#xD;
      entered into the study and randomised in a 1:1:1:1 ratio to receive SY-005 2.5mg or SY-005&#xD;
      5mg or SY-005 10mg or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability Parameters of SY-005</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
    <description>Number of patients with treatment-emergent adverse events over 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sequential Organ Failure Assessment (SOFA) Score at Day 1, Day3, Day5, Day7</measure>
    <time_frame>Baseline, Day 1, Day3, Day5, Day7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressin Free Days From Day 0 to Day 28</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of ICU-Free Days From Day 0 to Day 28</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-Free Days From Day 0 to Day 28</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-Day and 28-Day Mortality</measure>
    <time_frame>Over 7/28 Days Following First Dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IL-1β at Day 3，Day5</measure>
    <time_frame>Baseline, Day 3，Day5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IL-6 at Day 3，Day5</measure>
    <time_frame>Baseline, Day 3，Day5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Procalcitonin at Day 3，Day5</measure>
    <time_frame>Baseline, Day 3，Day5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Prothrombin Time at Day 3，Day5</measure>
    <time_frame>Baseline, Day 3，Day5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Thrombin Time at Day 3，Day5</measure>
    <time_frame>Baseline, Day 3，Day5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Activated Partial Thromboplastin Time at Day 3，Day5</measure>
    <time_frame>Baseline, Day 3，Day5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fibrinogen at Day 3，Day5</measure>
    <time_frame>Baseline, Day 3，Day5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemokine(C-C motif) Ligand 2 at Day 3，Day5</measure>
    <time_frame>Baseline, Day 3，Day5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Anti-drug Antibodies at Day7，Day14，Day28</measure>
    <time_frame>Baseline, Day7，Day14，Day28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>2.5mg SY-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5mg SY-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg SY-005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-005</intervention_name>
    <description>2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days</description>
    <arm_group_label>2.5mg SY-005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-005</intervention_name>
    <description>5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days</description>
    <arm_group_label>5mg SY-005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-005</intervention_name>
    <description>10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days</description>
    <arm_group_label>10mg SY-005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Patients are diagnosed with sepsis and receive study treatment within 48 hours&#xD;
&#xD;
          -  Sepsis-related Organ Failure Assessment（SOFA）score range from 2 to 13&#xD;
&#xD;
          -  The informed consent form signed by the patient or the patient's legally acceptable&#xD;
             representative&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women ; Women of childbearing potential (WOCBP) could not&#xD;
             take effective method of contraception&#xD;
&#xD;
          -  Moribund, and death is considered imminent within 24 hours or patient expected&#xD;
             survival time is less than 6 months due to the underlying disease&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;0.5 x 10^9/L&#xD;
&#xD;
          -  New York Heart Association (NYHA) classification IV&#xD;
&#xD;
          -  Patient with end-stage lung disease&#xD;
&#xD;
          -  eGFR &lt;60ml/min&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;3.0 times the&#xD;
             upper limit of normal (ULN)&#xD;
&#xD;
          -  Immunosuppressed patients with following situations:&#xD;
&#xD;
               1. Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
               2. Patients undergoing active radiation or chemotherapy treatment within the past 3&#xD;
                  months&#xD;
&#xD;
               3. Any organ or bone marrow transplant and related immunosuppressive therapy&#xD;
&#xD;
               4. High dose steroids (eg, &gt; 0.5 mg/kg prednisone or a steroid with equivalent&#xD;
                  activity, daily for a month) within 3 months before provision of written informed&#xD;
                  consent for the study&#xD;
&#xD;
          -  Patients with high bleeding risk:&#xD;
&#xD;
               1. Recent surgery &lt;72 hours, or a planned surgical procedure in the next 24h&#xD;
&#xD;
               2. Severe thrombocytopenia (&lt; 30 x 10^9/L, before platelet transfusion)&#xD;
&#xD;
               3. Recent trauma &lt;72 hours&#xD;
&#xD;
               4. History of gastrointestinal bleeding or intracranial hemorrhage in the past 6&#xD;
                  weeks.&#xD;
&#xD;
               5. Stroke or head injury in the past 3 months&#xD;
&#xD;
               6. On-going therapeutic anticoagulants that could not be interrupted (except&#xD;
                  prophylactic heparin treatment that can be continued）&#xD;
&#xD;
               7. Any history of Chronic liver disease with a Child score B or C&#xD;
&#xD;
               8. Any condition at risk of bleeding, as appreciated by the physician in charge of&#xD;
                  the patient&#xD;
&#xD;
          -  Severe anemia (hemoglobin &lt;5.9 g/dL)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yi Yang</last_name>
    <phone>+86 025-83272015</phone>
    <email>yiyiyang2004@163.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

